Fig. 1: Survival outcomes of 21 patients on blinatumomab maintenance post allo-HSCT.

Survival curves plotted against number of days after allo-HSCT for (A) overall survival (OS), (B) event-free survival (EFS), (C) GvHD-free and relapse-free survival (GRFS), (D) relapse. The data is presented as percentage with 95%CI.